AlphaCrest Capital Management’s Travere Therapeutics TVTX Stock Holding History

AlphaCrest Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12,107	Closed	-$298K	–	1067
2022 Q3	$298K	Buy	12,107 +1,435	+13%	+$37.1K	0.02%	1141
2022 Q2	$259K	Sell	10,672 -9,781	-48%	-$246K	0.01%	1155
2022 Q1	$527K	Sell	20,453 -35,338	-63%	-$938K	0.03%	870
2021 Q4	$1.73M	Buy	+55,791	New	+$1.57M	0.06%	502
2021 Q3	–	Sell	-49,400	Closed	-$721K	–	1386
2021 Q2	$721K	Buy	+49,400	New	+$974K	0.03%	806
2020 Q4	–	Sell	-12,500	Closed	-$231K	–	1276
2020 Q3	$231K	Buy	+12,500	New	+$243K	0.03%	988
2020 Q1	–	Sell	-14,100	Closed	-$200K	–	1280
2019 Q4	$200K	Sell	14,100 -11,200	-44%	-$143K	0.02%	1209
2019 Q3	$293K	Buy	+25,300	New	+$418K	0.02%	1101

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AlphaCrest Capital Management's TVTX Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Travere Therapeutics (TVTX) in Q4 2022, closing a stake of 12,107 shares — an estimated $298K sold.

AlphaCrest Capital Management first reported a position in TVTX in Q3 2019 and held it in 8 quarters. The position peaked at $1.73M in Q4 2021. 155 funds tracked by Wall St. Rank hold TVTX as of Q4 2022.

AlphaCrest Capital Management reported no remaining Travere Therapeutics position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 12,107 Travere Therapeutics shares in Q4 2022, an estimated $298K.
AlphaCrest Capital Management first reported a position in Travere Therapeutics in Q3 2019 and held it in 8 quarters.
AlphaCrest Capital Management's Travere Therapeutics position peaked at $1.73M in Q4 2021.
155 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.